53 related articles for article (PubMed ID: 10556192)
1. DUSP22-IRF4 Rearranged CD30-Positive Primary Cutaneous Lymphoproliferative Disorder With Gamma/Delta Phenotype.
Fattah YH; Crasto D; Liu SS; Linhares Y; Kerdel F; Hanly A; Karai LJ
Am J Dermatopathol; 2023 Dec; 45(12):831-834. PubMed ID: 37883980
[TBL] [Abstract][Full Text] [Related]
2. Increase in CD30 ligand/CD153 and TNF-alpha expressing mast cells in basal cell carcinoma.
Diaconu NC; Kaminska R; Naukkarinen A; Harvima RJ; Nilsson G; Harvima IT
Cancer Immunol Immunother; 2007 Sep; 56(9):1407-15. PubMed ID: 17268792
[TBL] [Abstract][Full Text] [Related]
3. Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal antibody.
Di Paola R; Di Marco R; Mazzon E; Genovese T; Bendtzen K; Macrì B; Nicoletti F; Cuzzocrea S
Clin Immunol; 2004 Oct; 113(1):64-73. PubMed ID: 15380531
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous Intravascular Hematolymphoid Entities: A Review.
Marshall EH; Brumbaugh B; Holt A; Chen ST; Hoang MP
Diagnostics (Basel); 2024 Mar; 14(7):. PubMed ID: 38611591
[TBL] [Abstract][Full Text] [Related]
5. Correction to: IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas.
Am J Clin Pathol; 2024 Jan; 161(1):107. PubMed ID: 37991998
[No Abstract] [Full Text] [Related]
6. Lymphomatoid Papulosis Development in Acute Lymphoblastic Leukemia.
Oura K; Sato T; Iguchi A; Toriumi N; Sarashina T
J Med Cases; 2021 Aug; 12(8):306-309. PubMed ID: 34434478
[TBL] [Abstract][Full Text] [Related]
7. CD30
Sauder MB; O'Malley JT; LeBoeuf NR
Hematol Oncol Clin North Am; 2017 Apr; 31(2):317-334. PubMed ID: 28340881
[TBL] [Abstract][Full Text] [Related]
8. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
Hu S; Xu-Monette ZY; Balasubramanyam A; Manyam GC; Visco C; Tzankov A; Liu WM; Miranda RN; Zhang L; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhao X; Winter JN; Zhang M; Li L; Møller MB; Piris MA; Li Y; Go RS; Wu L; Medeiros LJ; Young KH
Blood; 2013 Apr; 121(14):2715-24. PubMed ID: 23343832
[TBL] [Abstract][Full Text] [Related]
9. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells.
Kober J; Leitner J; Klauser C; Woitek R; Majdic O; Stöckl J; Herndler-Brandstetter D; Grubeck-Loebenstein B; Reipert BM; Pickl WF; Pfistershammer K; Steinberger P
Eur J Immunol; 2008 Oct; 38(10):2678-88. PubMed ID: 18825741
[TBL] [Abstract][Full Text] [Related]
10. Regulation of CD30 antigen expression and its potential significance for human disease.
Kadin ME
Am J Pathol; 2000 May; 156(5):1479-84. PubMed ID: 10793058
[No Abstract] [Full Text] [Related]
11. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin's disease and anaplastic large cell lymphoma.
Hsu PL; Hsu SM
Lab Invest; 2000 Jul; 80(7):1111-9. PubMed ID: 10908157
[TBL] [Abstract][Full Text] [Related]
12. Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.
Di Raimondo C; Parekh V; Song JY; Rosen ST; Querfeld C; Zain J; Martinez XU; Abdulla FR
Curr Hematol Malig Rep; 2020 Aug; 15(4):333-342. PubMed ID: 32435988
[TBL] [Abstract][Full Text] [Related]
13. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
Kartan S; Johnson WT; Sokol K; Alpdogan O; Gru AA; Nikbakht N; Porcu P
Chin Clin Oncol; 2019 Feb; 8(1):3. PubMed ID: 30691273
[TBL] [Abstract][Full Text] [Related]
14. CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression.
Mori M; Manuelli C; Pimpinelli N; Mavilia C; Maggi E; Santucci M; Bianchi B; Cappugi P; Giannotti B; Kadin ME
Blood; 1999 Nov; 94(9):3077-83. PubMed ID: 10556192
[TBL] [Abstract][Full Text] [Related]
15. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin.
Gattei V; Degan M; Gloghini A; De Iuliis A; Improta S; Rossi FM; Aldinucci D; Perin V; Serraino D; Babare R; Zagonel V; Gruss HJ; Carbone A; Pinto A
Blood; 1997 Mar; 89(6):2048-59. PubMed ID: 9058727
[TBL] [Abstract][Full Text] [Related]
16. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.
Gruss HJ; DaSilva N; Hu ZB; Uphoff CC; Goodwin RG; Drexler HG
Leukemia; 1994 Dec; 8(12):2083-94. PubMed ID: 7528856
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
